Floatz logo

Ponatinib

Philadelphia-Positive ALL

University of AlbertaSmall moleculePhase 3Active
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
53/ 100
Competitive Position
89/ 100

Competitive context

34 Active assets in the Philadelphia-Positive ALL cohort.

Asset / SponsorPhaseRating
Nilotinib
The University of Hong Kong
Phase 2BBB
Cytosin-Arabinosid
Novartis Pharmaceuticals
Phase 3BBB
Blinatumomab
Novartis Pharmaceuticals
Phase 3BBB
METHOTREXATE
Novartis Pharmaceuticals
Phase 3BB
Imatinib
The University of Hong Kong
Phase 3BB

View all 50 →

Same molecule, other indications

Ponatinib is also rated in:

chronic myeloid leukemiaDormant
BB
Indicative ·
66 / 100
View asset →
blast phase chronic myelogenous leukemia, BCR-ABL1 positiveDormant
BB
Indicative ·
65 / 100
View asset →
acute lymphoblastic leukemiaDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →